Cargando…
Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction
Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD)(1) and is also linked to its idiopathic form(2). LRRK2 is proposed to function in membrane trafficking(3) and co-localizes with microtubules(4). Despite LRRK2’s fundamental importance for unde...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726071/ https://www.ncbi.nlm.nih.gov/pubmed/32814344 http://dx.doi.org/10.1038/s41586-020-2673-2 |
_version_ | 1783620809226452992 |
---|---|
author | Deniston, CK Salogiannis, J Mathea, S Snead, DM Lahiri, I Matyszewski, M Donosa, O Watanabe, R Böhning, J Shiau, AK Knapp, S Villa, E Reck-Peterson, SL Leschziner, AE |
author_facet | Deniston, CK Salogiannis, J Mathea, S Snead, DM Lahiri, I Matyszewski, M Donosa, O Watanabe, R Böhning, J Shiau, AK Knapp, S Villa, E Reck-Peterson, SL Leschziner, AE |
author_sort | Deniston, CK |
collection | PubMed |
description | Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD)(1) and is also linked to its idiopathic form(2). LRRK2 is proposed to function in membrane trafficking(3) and co-localizes with microtubules(4). Despite LRRK2’s fundamental importance for understanding and treating PD, there is limited structural information on it. Here we report the 3.5Å structure of the catalytic half of LRRK2, and an atomic model of microtubule-associated LRRK2 built using a reported 14Å cryo-electron tomography in situ structure(5). We propose that the conformation of LRRK2’s kinase domain regulates its microtubule interaction, with a closed conformation favoring oligomerization on microtubules. We show that the catalytic half of LRRK2 is sufficient for filament formation and blocks the motility of the microtubule-based motors kinesin-1 and cytoplasmic dynein-1 in vitro. Kinase inhibitors that stabilize an open conformation relieve this interference and reduce LRRK2 filament formation in cells, while those that stabilize a closed conformation do not. Our findings suggest that LRRK2 can act as a roadblock for microtubule-based motors and have implications for the design of therapeutic LRRK2 kinase inhibitors. |
format | Online Article Text |
id | pubmed-7726071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-77260712021-02-19 Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction Deniston, CK Salogiannis, J Mathea, S Snead, DM Lahiri, I Matyszewski, M Donosa, O Watanabe, R Böhning, J Shiau, AK Knapp, S Villa, E Reck-Peterson, SL Leschziner, AE Nature Article Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD)(1) and is also linked to its idiopathic form(2). LRRK2 is proposed to function in membrane trafficking(3) and co-localizes with microtubules(4). Despite LRRK2’s fundamental importance for understanding and treating PD, there is limited structural information on it. Here we report the 3.5Å structure of the catalytic half of LRRK2, and an atomic model of microtubule-associated LRRK2 built using a reported 14Å cryo-electron tomography in situ structure(5). We propose that the conformation of LRRK2’s kinase domain regulates its microtubule interaction, with a closed conformation favoring oligomerization on microtubules. We show that the catalytic half of LRRK2 is sufficient for filament formation and blocks the motility of the microtubule-based motors kinesin-1 and cytoplasmic dynein-1 in vitro. Kinase inhibitors that stabilize an open conformation relieve this interference and reduce LRRK2 filament formation in cells, while those that stabilize a closed conformation do not. Our findings suggest that LRRK2 can act as a roadblock for microtubule-based motors and have implications for the design of therapeutic LRRK2 kinase inhibitors. 2020-08-19 2020-12 /pmc/articles/PMC7726071/ /pubmed/32814344 http://dx.doi.org/10.1038/s41586-020-2673-2 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Deniston, CK Salogiannis, J Mathea, S Snead, DM Lahiri, I Matyszewski, M Donosa, O Watanabe, R Böhning, J Shiau, AK Knapp, S Villa, E Reck-Peterson, SL Leschziner, AE Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction |
title | Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction |
title_full | Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction |
title_fullStr | Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction |
title_full_unstemmed | Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction |
title_short | Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction |
title_sort | structure of lrrk2 in parkinson’s disease and model for microtubule interaction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726071/ https://www.ncbi.nlm.nih.gov/pubmed/32814344 http://dx.doi.org/10.1038/s41586-020-2673-2 |
work_keys_str_mv | AT denistonck structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT salogiannisj structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT matheas structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT sneaddm structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT lahirii structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT matyszewskim structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT donosao structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT watanaber structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT bohningj structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT shiauak structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT knapps structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT villae structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT reckpetersonsl structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction AT leschzinerae structureoflrrk2inparkinsonsdiseaseandmodelformicrotubuleinteraction |